KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Common Equity (2016 - 2025)

Historic Common Equity for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $7.5 billion.

  • Bio-Rad Laboratories' Common Equity rose 1346.11% to $7.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.5 billion, marking a year-over-year increase of 1346.11%. This contributed to the annual value of $7.5 billion for FY2025, which is 1346.11% up from last year.
  • Latest data reveals that Bio-Rad Laboratories reported Common Equity of $7.5 billion as of Q4 2025, which was up 1346.11% from $6.7 billion recorded in Q3 2025.
  • Bio-Rad Laboratories' Common Equity's 5-year high stood at $15.3 billion during Q3 2021, with a 5-year trough of $6.6 billion in Q4 2024.
  • For the 5-year period, Bio-Rad Laboratories' Common Equity averaged around $9.1 billion, with its median value being $8.6 billion (2022).
  • Its Common Equity has fluctuated over the past 5 years, first soared by 7373.51% in 2021, then crashed by 4470.87% in 2022.
  • Over the past 5 years, Bio-Rad Laboratories' Common Equity (Quarter) stood at $13.7 billion in 2021, then fell by 29.74% to $9.6 billion in 2022, then fell by 9.09% to $8.7 billion in 2023, then decreased by 24.85% to $6.6 billion in 2024, then rose by 13.46% to $7.5 billion in 2025.
  • Its last three reported values are $7.5 billion in Q4 2025, $6.7 billion for Q3 2025, and $7.1 billion during Q2 2025.